Rheumatoid arthritis

News

GSK, Verily-backed Galvani starts trials of bioelectronic ar...

The first patient has been treated with an implantable bioelectronic device developed by Galvani Therapeutics, set up by GlaxoSmithKline and Alphabet's Verily Life Sciences in 2016.

News

Actemra shortage spills over to include Sanofi's rival Kevza...

Roche's Actemra has been in high demand since its value in treating severe COVID-19 was established, leading to shortages.

News

FDA firms up JAK inhibitor warnings after Xeljanz review

The FDA has concluded its safety review of Pfizer's JAK inhibitor Xeljanz and Xeljanz XR, requiring revised warnings for the drugs as well as others in the class after finding evidence of e

News

Trials leave Galapagos' SIK programme looking under the weat...

Galapagos has had to send its SIK inhibitor programme back to the drawing board after its lead compound GLPG3970 has failed two of three clinical trials, adding to a string of disappointmen

News

FDA holds back from action over Xeljanz safety study

The FDA has said it will wait for additional results from last week’s trial showing an increased risk of cardiac side effects with Pfizer’s arthritis blockbuster Xeljanz before deciding on

News

NICE backs broad use for Gilead/Galapagos arthritis pill Jys...

Patients with rheumatoid arthritis (RA) in England will be able to get treatment with Gilead Sciences and Galapagos’ JAK inhibitor Jyseleca, after it was backed by cost-effectiveness agency

GSK, Verily-backed Galvani starts trials of bioelectronic ar...

Actemra shortage spills over to include Sanofi's rival Kevza...

FDA firms up JAK inhibitor warnings after Xeljanz review

Trials leave Galapagos' SIK programme looking under the weat...

FDA holds back from action over Xeljanz safety study

NICE backs broad use for Gilead/Galapagos arthritis pill Jys...

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Rheumatoid arthritis

Editor's Picks